2013, Number 6
<< Back
Med Cutan Iber Lat Am 2013; 41 (6)
Refractory prurigo nodularis treated with thalidomide
Hernández Z, Liuti F, Almeida P, Borrego L, Hernández J
Language: Spanish
References: 10
Page: 281-282
PDF size: 81.89 Kb.
Text Extraction
No abstract.
REFERENCES
Accioly-Filho JW, Nogueria A, Ramos-e- Silva M. Prurigo nodularis of Hyde: an update. J Eur Acad Dermatol Venereol 2000; 14: 75-82.
Sharma LN, Sharma VC, Mahajan VK, Shanker V, Ranjan N, Gupta M. Thalidomide: An experience in therapeutic outcome and adverse reactions. J Dermatolog Treat 2007; 18: 335-40.
Cheng M, Doherty SD, Hsu S. Innovative uses of Thalidomide. Dermatol Clin 2010; 28: 577-86.
Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanisms of action and sideeffects. Br J Dermatol 2005; 153: 254-73.
Sheskin J. Thalidomiede in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-6.
Andersen TP, Fogh K. Thalidomide in 42 patients with Prurigo Nodularis Hyde. Dermatology 2011; 223: 107-12.
Wines NY, Cooper AJ, Wines MP. Thalidomide in dermatology. Australas J Dermatol 2002; 43: 229-40.
Tseng S, Pak G, Washenuk K, Pomeranz MK, Shupack JL. Rediscovering thalidomide. A review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-79.
Lan CC, Lin CL, Wu CS, Chai CY, Chen WT, Chen GS. Treatment of idiopathic prurigo nodularis in Taiwanese patients with lowdose thalidomide. J Dermatol 2007; 34: 237-42.
Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z et al. Incidence and Risk Factors for Thalidomide Neuropathy: a Prospective Study of 135 Dermatologic Patients. J Invest Dermatol 2002; 119: 1020-6.
Full text